S&P 500   2,993.14 (-0.16%)
DOW   26,840.76 (-0.68%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
MSFT   138.05 (-1.17%)
GOOGL   1,245.66 (-0.57%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
NVDA   190.73 (-1.83%)
BABA   170.36 (-3.67%)
GE   8.99 (-0.55%)
TSLA   256.90 (-1.94%)
AMD   30.81 (-1.06%)
GILD   64.23 (-1.53%)
S&P 500   2,993.14 (-0.16%)
DOW   26,840.76 (-0.68%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
MSFT   138.05 (-1.17%)
GOOGL   1,245.66 (-0.57%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
NVDA   190.73 (-1.83%)
BABA   170.36 (-3.67%)
GE   8.99 (-0.55%)
TSLA   256.90 (-1.94%)
AMD   30.81 (-1.06%)
GILD   64.23 (-1.53%)
Log in

Nuo Therapeutics Stock Price, News & Analysis (OTCMKTS:NUOTQ)

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.01
0.00 (0.00 %)
(As of 05/11/2016)
Add
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range N/A
52-Week Range
$0.00
Now: $0.01
$0.29
VolumeN/A
Average Volume304,122 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Nuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:NUOTQ
Previous SymbolOTCMKTS:CMXI
CUSIPN/A
CIKN/A
Phone+1-240-4992680

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive NUOTQ News and Ratings via Email

Sign-up to receive the latest news and ratings for NUOTQ and its competitors with MarketBeat's FREE daily newsletter.


Nuo Therapeutics (OTCMKTS:NUOTQ) Frequently Asked Questions

What is Nuo Therapeutics' stock symbol?

Nuo Therapeutics trades on the OTCMKTS under the ticker symbol "NUOTQ."

Has Nuo Therapeutics been receiving favorable news coverage?

News coverage about NUOTQ stock has trended neutral recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nuo Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Nuo Therapeutics.

Who are Nuo Therapeutics' key executives?

Nuo Therapeutics' management team includes the folowing people:
  • David Emerson Jorden CPA, Chief Executive Officer, Chief Financial Officer, Director (Age 52)
  • Peter A. Clausen Ph.D., Chief Science Officer (Age 49)
  • Shaun C Martin, Chief Restructuring Officer
  • Lawrence Atinsky, Director
  • Paul D. Mintz M.D., Director
  • Lyle A. Hohnke Ph.D., Independent Director (Age 72)
  • Mark T. McLoughlin, Independent Director (Age 61)
  • C. Eric Winzer, Independent Director (Age 58)

What is Nuo Therapeutics' stock price today?

One share of NUOTQ stock can currently be purchased for approximately $0.01.

What is Nuo Therapeutics' official website?

The official website for Nuo Therapeutics is http://www.cytomedix.com/.

How can I contact Nuo Therapeutics?

Nuo Therapeutics' mailing address is 207a Perry Pkwy Ste 1, GAITHERSBURG, MD 20877-2196, United States. The company can be reached via phone at +1-240-4992680.


MarketBeat Community Rating for Nuo Therapeutics (OTCMKTS NUOTQ)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  105
MarketBeat's community ratings are surveys of what our community members think about Nuo Therapeutics and other stocks. Vote "Outperform" if you believe NUOTQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUOTQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel